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Metabolism and analysis of selected orally-active 17α-alkyl Steroids with anabolic 
potential in the horse 
 
This study tried to investigate the metabolism of the anabolic steroids 
dehydroepiandrosterone (DHA), methandriol (MAD) and 17α-methyltestosterone (17α-MT) 
in the Equine and to subsequently develop a gas-chromatographic / mass-spectrometric 
(gc/ms) screening method for the detection of the two latter orally-active anabolic agents. 
For each experiment 200 mg of the respective steroid were administered to two 
thoroughbred horses in training. The administered substances contained a mixture of the 
same amount of deuterated and non-deuterated steroid. Additionally, a radioactive isotop 
was administered in the DHA (3H-DHA and 14C-DHA) and MAD (3H-MAD) studies. In the 
case of 17α-MT no radioactive isotop was administered. 
Blood samples were taken at regular intervals for a three- up to a five-day period. Freely- 
voided urine was collected for the same period of time. The absorption and elimination of 
the administered steroids were determined by scintigraphy of the ß-emission in all radio 
labelled samples collected. Only the urine samples were subsequently extracted for the 
detection of possible steroid metabolites by gc/ms-analysis. 
The half-life of intramuscularly administered 3H-DHA ranged from between 9 to 12 h. The 
half-life of orally administered 14C-DHA was around 3 h in both horses and hence about ¼ to 
⅓ that of 3H-DHA. This can mainly be explained by the first-pass effect to which orally 
administered 14C-DHA had been exposed in the liver. The half-life of orally administered 3H-
MAD was 11.99 h for one of the two horses. This value is similar to the one for 
intramuscularly administered 3H-DHA. This would indicate that the 17α-alkylation has 
protected the orally administered MAD from the first-pass effect of the liver. For the second 
horse the half-life was only 3.75 h, which is similar to the one for orally administered 14C-
DHA being exposed to the first-pass effect of the liver. This large difference in half-life could 
not be explained. 
Overall, about 60% of the total intramuscularly administered 3H-DHA was excreted via the 
urine. For orally administered 14C-DHA and 3H-MAD this value was about 50%. In 3H-DHA 
and 3H-MAD ≥95% of the radioactive dose excreted via the urine had been excreted only 
after 50 h. For 14C-DHA this value had already been reached between 30-35 h after 
administration of the steroid. 
The urinalysis of the radioactively labelled steroids showed great losses of radioactivity, i.e., 




washing the extracts. Two main reasons were assumed for these losses: (1) it was thought 
that losses which occurred into the urine after extraction were at least partly caused by 
capacity problems of the cartridges used; whereas (2) losses into solutions used for washing 
the different extracts might have their origin in the existence of a number of very polar 
metabolite(s), which were hence “washed out” of the lipophilic extracts by the hydrophilic 
wash solutions used. 
Due to these losses the gc/ms analysis of DHA and MAD partly showed rather 
unsatisfactory results; most of the detected metabolites were only present in very low 
concentrations. This resulted in difficulties to assign the appropriate chemical structure to a 
number of the detected metabolites. 
In general, DHA and its metabolites were excreted only to a very low percentage as free 
steroids (< 2%). About 10-15% were excreted as conjugates with glucuronic acid while 
around 60% of the metabolites showed a conjugation with sulphuric acid. The excretion 
pattern of MAD and its metabolites showed similar results; where only around 4% were 
excreted as free steroid, while 10-15% were excreted as conjugates of glucuronic acid and 
around 50% as conjugates of sulphuric acid. 
The following three metabolites have been determined for DHA:  
1. 3ß-Hydroxyandrost-5-en-17-one (I = parent drug),  
2. 5-Androsten-3,17-diol (II/4 isomers), and 
3. 5-Androstane-3,17-diol (III/2 isomers). 
The following five metabolites have been determined for MAD: 
1. 17α-Methyl-5-androsten-3ß,17ß-diol (I/2 isomers = parent drug), 
2. 17-Hydroxy-17α-Methyl-5-androstane-3ß-ol (II),  
3. 17-Hydroxy-17α-Methyl-5-androstane-3,(15/16)-diol (IV), 
4. 17-Hydroxy-17α-Methyl-5-androstane-3,(6/7),16-triol (V/2 isomers), 
5. 17-Hydroxy-17α-Methyl-androst-4-en-(6/7),16-diol-3-one (VI), as well as 
Since in the case of 17α-MT no radioactively labelled isotope had been administered no 
information could be obtained about the absorption or excretion profile, the plasma half-life 
of the substance or the extent of its phase-II metabolism in the horse. 
The gc/ms analysis of this steroid though showed a large number of metabolites present in 
the analysed extracts in viable concentrations. It was therefore assumed that the losses 
during urinalysis as described for DHA and MAD did not occur at all or only to a much lesser 
extend in the case of 17α-MT. 
The following 12 metabolites have been determined for 17α-MT: 















For MAD the prerequisite for the establishment of a routine detection method is the 
optimization of the method used, which in its current form does not yet yield sufficient results 
viable to be included into a screening-analysis procedure. 
For 17α-MT instead the search for metabolites 2, 6, 7 and 9 during a routine gc/ms 
screening analysis is considered sufficient to prove the administration of 17α-MT to the 
horse for doping purposes. Using 'single ion monitoring (SIM)' it should be screened for the 
fragment ions with the mass-to-charge (m/z) ratios m/z 143, m/z 218 and m/z 231 since they 
are characteristic for all 17α-methylated steroids. This method allows the detection of a 17α-
MT application to the horse for a period of at least 50 h after administration. Since in the 
course of this study no later urine samples had been collected, additional studies will be 
needed to determine the maximum time of detection after administration of 17α-MT to a 
horse for doping purposes when using this method of extraction and analysis. 
